TWI278625B - Automated semi-solid matrix assay and liquid handler apparatus for the same - Google Patents
Automated semi-solid matrix assay and liquid handler apparatus for the same Download PDFInfo
- Publication number
- TWI278625B TWI278625B TW091102250A TW91102250A TWI278625B TW I278625 B TWI278625 B TW I278625B TW 091102250 A TW091102250 A TW 091102250A TW 91102250 A TW91102250 A TW 91102250A TW I278625 B TWI278625 B TW I278625B
- Authority
- TW
- Taiwan
- Prior art keywords
- liquid
- semi
- storage tank
- analysis
- cells
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 226
- 238000003556 assay Methods 0.000 title claims abstract description 32
- 239000007787 solid Substances 0.000 title claims description 213
- 239000011159 matrix material Substances 0.000 title claims description 147
- 150000001875 compounds Chemical class 0.000 claims abstract description 186
- 238000000034 method Methods 0.000 claims abstract description 116
- 238000002156 mixing Methods 0.000 claims abstract description 41
- 238000012546 transfer Methods 0.000 claims abstract description 26
- 238000010438 heat treatment Methods 0.000 claims abstract description 24
- 238000001816 cooling Methods 0.000 claims abstract description 22
- 230000033001 locomotion Effects 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 290
- 238000004458 analytical method Methods 0.000 claims description 233
- 229920001817 Agar Polymers 0.000 claims description 143
- 239000008272 agar Substances 0.000 claims description 142
- 229920000936 Agarose Polymers 0.000 claims description 97
- 238000003860 storage Methods 0.000 claims description 93
- 239000001963 growth medium Substances 0.000 claims description 91
- 238000012360 testing method Methods 0.000 claims description 83
- 239000000758 substrate Substances 0.000 claims description 62
- 206010028980 Neoplasm Diseases 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 42
- 210000004881 tumor cell Anatomy 0.000 claims description 40
- 238000010790 dilution Methods 0.000 claims description 33
- 239000012895 dilution Substances 0.000 claims description 33
- 238000012545 processing Methods 0.000 claims description 27
- 239000012530 fluid Substances 0.000 claims description 26
- 210000000130 stem cell Anatomy 0.000 claims description 26
- 239000002609 medium Substances 0.000 claims description 24
- 230000035899 viability Effects 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- 230000002079 cooperative effect Effects 0.000 claims description 18
- 238000007639 printing Methods 0.000 claims description 18
- 230000000007 visual effect Effects 0.000 claims description 14
- 230000007246 mechanism Effects 0.000 claims description 13
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000006073 displacement reaction Methods 0.000 claims description 11
- -1 glia Substances 0.000 claims description 9
- 230000001276 controlling effect Effects 0.000 claims description 8
- 108010082117 matrigel Proteins 0.000 claims description 8
- 230000032258 transport Effects 0.000 claims description 8
- 230000004071 biological effect Effects 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 238000001459 lithography Methods 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 210000002469 basement membrane Anatomy 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 3
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 210000004498 neuroglial cell Anatomy 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 1
- 230000002508 compound effect Effects 0.000 claims 1
- 230000006872 improvement Effects 0.000 claims 1
- 230000037452 priming Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 230000002285 radioactive effect Effects 0.000 abstract description 4
- 238000004166 bioassay Methods 0.000 abstract 1
- 235000010419 agar Nutrition 0.000 description 132
- 239000010410 layer Substances 0.000 description 73
- 239000000306 component Substances 0.000 description 36
- 230000012010 growth Effects 0.000 description 24
- 239000000523 sample Substances 0.000 description 22
- 238000011534 incubation Methods 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 16
- 229950010817 alvocidib Drugs 0.000 description 16
- 230000010261 cell growth Effects 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 239000003102 growth factor Substances 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 238000013207 serial dilution Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 238000001879 gelation Methods 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 239000002639 bone cement Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 238000007792 addition Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000002356 single layer Substances 0.000 description 8
- 231100000588 tumorigenic Toxicity 0.000 description 8
- 230000000381 tumorigenic effect Effects 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000032823 cell division Effects 0.000 description 6
- 239000013068 control sample Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 230000011681 asexual reproduction Effects 0.000 description 5
- 238000013465 asexual reproduction Methods 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 230000002028 premature Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 238000009434 installation Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 230000005355 Hall effect Effects 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 230000005679 Peltier effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000011319 anticancer therapy Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000005693 optoelectronics Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 210000005267 prostate cell Anatomy 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000012857 radioactive material Substances 0.000 description 3
- 238000007711 solidification Methods 0.000 description 3
- 230000008023 solidification Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 238000013334 tissue model Methods 0.000 description 3
- 241001474374 Blennius Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000002998 adhesive polymer Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000005059 solid analysis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- ZCWPHDXKEDBCER-UHFFFAOYSA-N 2,5-diphenyl-2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=CC=CC=C1C1=[NH+]N(C=2C=CC=CC=2)N=N1 ZCWPHDXKEDBCER-UHFFFAOYSA-N 0.000 description 1
- WZYRMLAWNVOIEX-BGPJRJDNSA-N 3,6-anhydro-D-galactose Chemical group O=C[C@H](O)[C@H]1OC[C@@H](O)[C@@H]1O WZYRMLAWNVOIEX-BGPJRJDNSA-N 0.000 description 1
- AUUIARVPJHGTSA-UHFFFAOYSA-N 3-(aminomethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(CN)=CC2=C1 AUUIARVPJHGTSA-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-VVKOMZTBSA-N Dideuterium Chemical compound [2H][2H] UFHFLCQGNIYNRP-VVKOMZTBSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 101710172177 Fasciclin-2 Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 238000011511 automated evaluation Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012809 cooling fluid Substances 0.000 description 1
- 239000000112 cooling gas Substances 0.000 description 1
- 239000000110 cooling liquid Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000012836 liquid overlay method Methods 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000010644 positive regulation of cell differentiation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000000693 radiobiological effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/10—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
- G01N35/1081—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices characterised by the means for relatively moving the transfer device and the containers in an horizontal plane
- G01N35/1083—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices characterised by the means for relatively moving the transfer device and the containers in an horizontal plane with one horizontal degree of freedom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/02—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
- G01N35/028—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations having reaction cells in the form of microtitration plates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/06—Investigating concentration of particle suspensions
- G01N15/075—Investigating concentration of particle suspensions by optical means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
- G01N15/1433—Signal processing using image recognition
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N2015/0092—Monitoring flocculation or agglomeration
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1486—Counting the particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N2035/00346—Heating or cooling arrangements
- G01N2035/00356—Holding samples at elevated temperature (incubation)
- G01N2035/00366—Several different temperatures used
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/02—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
- G01N35/04—Details of the conveyor system
- G01N2035/0401—Sample carriers, cuvettes or reaction vessels
- G01N2035/0418—Plate elements with several rows of samples
- G01N2035/0422—Plate elements with several rows of samples carried on a linear conveyor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/10—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
- G01N2035/1027—General features of the devices
- G01N2035/103—General features of the devices using disposable tips
Landscapes
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26964501P | 2001-02-16 | 2001-02-16 | |
| GBGB0117706.2A GB0117706D0 (en) | 2001-02-16 | 2001-07-20 | Automated semi-solid matrix assay and liquid handler apparatus for the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI278625B true TWI278625B (en) | 2007-04-11 |
Family
ID=26246333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW091102250A TWI278625B (en) | 2001-02-16 | 2002-02-07 | Automated semi-solid matrix assay and liquid handler apparatus for the same |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080293090A1 (fr) |
| EP (1) | EP1370876A2 (fr) |
| AR (1) | AR032703A1 (fr) |
| TW (1) | TWI278625B (fr) |
| WO (1) | WO2002066991A2 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI666061B (zh) * | 2014-08-27 | 2019-07-21 | 日商艾安得股份有限公司 | Pipette holder |
| TWI795744B (zh) * | 2020-03-18 | 2023-03-11 | 日商椿本鏈條股份有限公司 | 低溫保管系統 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006121886A1 (fr) * | 2005-05-06 | 2006-11-16 | Kalypsys, Inc. | Criblage automatise de composes utilisant une matrice de permeation sur gel et un transfert d'echantillons a broches |
| US8309036B2 (en) * | 2009-05-15 | 2012-11-13 | Gen-Probe Incorporated | Method for separating viscous materials suspended from a pipette |
| GB201121959D0 (en) * | 2011-12-21 | 2012-02-01 | Univ Leeds | Assay of functional cell viability |
| CN106459865B (zh) * | 2014-06-17 | 2019-01-08 | 雅马哈发动机株式会社 | 缸型尖头安装头、使用该缸型尖头安装头的头装置以及移动装置 |
| US10286564B2 (en) * | 2017-05-01 | 2019-05-14 | Lincoln Global, Inc. | System for locally generating electricity on a robotic device |
| CN114276896B (zh) * | 2021-12-22 | 2023-12-29 | 成都瀚辰光翼科技有限责任公司 | 一种自动化核酸提取方法及存储介质 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3844896A (en) * | 1970-10-29 | 1974-10-29 | Lever Brothers Ltd | Apparatus for performing bacteriological tests automatically |
| US3772154A (en) * | 1971-05-03 | 1973-11-13 | Technicon Instr | Method and apparatus for automated antibiotic susceptibility analysis of bacteria samples |
| NL7704460A (nl) * | 1977-04-22 | 1978-10-24 | Vitatron Scientific Bv | Analyse-automaat. |
| US4952518A (en) * | 1984-10-01 | 1990-08-28 | Cetus Corporation | Automated assay machine and assay tray |
| DE185330T1 (de) * | 1984-12-18 | 1986-11-27 | Cetus Corp., Emeryville, Calif. | System zur behandlung mehrfacher proben. |
| DE3903778A1 (de) * | 1989-02-09 | 1990-08-16 | Bruker Analytische Messtechnik | Verfahren zur schnellen pruefung der wirksamkeit von agenzien auf mikroorganismen und vorrichtung zur durchfuehrung des verfahrens |
| WO1991001365A1 (fr) * | 1989-07-18 | 1991-02-07 | Oncogene Science, Inc. | Appareil de laboratoire automatise |
| WO1991016675A1 (fr) * | 1990-04-06 | 1991-10-31 | Applied Biosystems, Inc. | Laboratoire de biologie moleculaire automatise |
| US5242806A (en) * | 1990-05-07 | 1993-09-07 | Baxter Diagnostics Inc. | Method for conducting the cytotoxicity assays on tumor cells |
| DE4210963A1 (de) * | 1992-04-02 | 1993-10-07 | Baxter Deutschland | Automatische Vorrichtung zur photometrischen Analyse von flüssigen Proben |
| US5756304A (en) * | 1995-07-14 | 1998-05-26 | Molecular Solutions | Screening of microorganisms for bioremediation |
-
2002
- 2002-02-05 EP EP02723094A patent/EP1370876A2/fr not_active Withdrawn
- 2002-02-05 WO PCT/US2002/003297 patent/WO2002066991A2/fr not_active Application Discontinuation
- 2002-02-07 TW TW091102250A patent/TWI278625B/zh not_active IP Right Cessation
- 2002-02-15 AR ARP020100526A patent/AR032703A1/es unknown
-
2008
- 2008-05-08 US US12/117,297 patent/US20080293090A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI666061B (zh) * | 2014-08-27 | 2019-07-21 | 日商艾安得股份有限公司 | Pipette holder |
| TWI795744B (zh) * | 2020-03-18 | 2023-03-11 | 日商椿本鏈條股份有限公司 | 低溫保管系統 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1370876A2 (fr) | 2003-12-17 |
| US20080293090A1 (en) | 2008-11-27 |
| WO2002066991A3 (fr) | 2003-04-10 |
| WO2002066991A2 (fr) | 2002-08-29 |
| AR032703A1 (es) | 2003-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040033554A1 (en) | Automated semi-solid matrix assay and liquid handler apparatus for the same | |
| US9557249B2 (en) | Instrument, apparatuses and devices for pretreating cells | |
| AU2008317329B2 (en) | Improved methods and devices for cellular analysis | |
| US9797008B2 (en) | Automated nucleic acid processor and automated nucleic acid processing method using multi function dispensing unit | |
| CA2255658C (fr) | Procede et appareil pour commander des particules magnetiques a l'aide d'une machine de pipettage | |
| US20080293090A1 (en) | Automated semi-solid matrix assay and liquid handler apparatus for the same | |
| JP7212523B2 (ja) | スクリーニングキットおよび方法 | |
| JP4755346B2 (ja) | 細胞培養の分析を実施する装置 | |
| JP2002065240A (ja) | 両生類卵母細胞試料導入装置、両生類卵母細胞試料導入システム、両生類卵母細胞試料導入方法、両生類卵母細胞の製造方法、両生類卵母細胞及びそれを販売又は譲渡する方法、スクリーニング用のセンサーとして用いる方法、容器、及び解析方法 | |
| US20090215104A1 (en) | Bioreactor Device, and Method and System for Fabricating Tissues in the Bioreactor Device | |
| US20120028298A1 (en) | System and method for automated tissue slide processing and data management | |
| JP2009525756A (ja) | 温度制御された培養プレート | |
| CN104412109A (zh) | 细胞培养和梯度迁移化验方法和装置 | |
| WO2008118500A1 (fr) | Plaque de perfusion de substance nutritive avec chauffage et échange de gaz pour criblage de contenu élevé | |
| JPWO2014077400A1 (ja) | 直動型反応処理装置およびその方法 | |
| CN102089427B (zh) | 细胞分散方法、细胞分散剂及细胞测定方法 | |
| Bregenzer et al. | Physiologic patient derived 3D spheroids for anti-neoplastic drug screening to target cancer stem cells | |
| JP2022532082A (ja) | オルガノイド培養のためのシステムおよび方法 | |
| CN115948339A (zh) | 高通量气液交界法培养神经胶质瘤类器官的方法 | |
| TW202235842A (zh) | 用於個人化醫療及藥物開發之微器官球體(micro-organospheres) | |
| CN114015741A (zh) | 一种非侵入式的微生物活性分析方法、系统 | |
| KR102132630B1 (ko) | 섬 구조물을 포함하는 신속한 세포배양검사 장치 | |
| WO1996030760A1 (fr) | Procede d'identification de substances biologiquement actives de par leur effet sur des cellules vivantes | |
| US5721135A (en) | Apparatus for identifying biologically active substances by their effect on living cells | |
| Vidic et al. | PREDECT protocols for complex 2D/3D cultures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |